Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
about
Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromesIron depletion suppresses mTORC1-directed signalling in intestinal Caco-2 cells via induction of REDD1.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
P2860
Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Deferasirox: a review of its u ...... fusion-dependent thalassaemia.
@en
type
label
Deferasirox: a review of its u ...... fusion-dependent thalassaemia.
@en
prefLabel
Deferasirox: a review of its u ...... fusion-dependent thalassaemia.
@en
P2860
P1433
P1476
Deferasirox: a review of its u ...... fusion-dependent thalassaemia.
@en
P2093
Matt Shirley
P2860
P2888
P304
P356
10.1007/S40265-014-0238-0
P577
2014-06-01T00:00:00Z
P6179
1035784037